RNA Interference Prevents Autosomal-Dominant Hearing Loss  by Shibata, Seiji B. et al.
ARTICLE
RNA Interference Prevents
Autosomal-Dominant Hearing Loss
Seiji B. Shibata,1,2,8 Paul T. Ranum,2,3,8 Hideaki Moteki,2,4 Bifeng Pan,5 Alexander T. Goodwin,2
Shawn S. Goodman,6 Paul J. Abbas,6 Jeffrey R. Holt,5 and Richard J.H. Smith1,2,3,7,*
Hearing impairment is themost common sensory deficit. It is frequently caused by the expression of an allele carrying a single dominant
missense mutation. Herein, we show that a single intracochlear injection of an artificial microRNA carried in a viral vector can slow
progression of hearing loss for up to 35 weeks in the Beethoven mouse, a murine model of non-syndromic human deafness caused by
a dominant gain-of-function mutation in Tmc1 (transmembrane channel-like 1). This outcome is noteworthy because it demonstrates
the feasibility of RNA-interference-mediated suppression of an endogenous deafness-causing allele to slow progression of hearing loss.
Given that most autosomal-dominant non-syndromic hearing loss in humans is caused by this mechanism of action, microRNA-based
therapeutics might be broadly applicable as a therapy for this type of deafness.Introduction
Hearing impairment is the most common sensory deficit.
It affects more than 360 million people worldwide and
broadly impacts their quality of life (see Web Resources).1
Not only does it limit the ability to interpret speech sounds
(leading to delayed language acquisition in infancy), but in
adulthood hearing impairment can lead to economic
disadvantage, social isolation, and stigmatization. Current
treatment options focus on hearing aids and cochlear im-
plants to bypass the biologic deficit by amplifying sounds
(hearing aids) or by encoding them as electrical impulses
that are transmitted to the auditory nerve through an im-
planted electrode array (cochlear implants). Although
these two habilitation options are effective, they do not
restore ‘‘normal’’ hearing. As life expectancy improves
and populations grow, the hearing-impaired population
will increase, making the development of therapeutics to
restore or prevent hearing loss important to enhancing
quality of life.2
Over the past decade, we have focused on RNA interfer-
ence (RNAi) as a means of selectively suppressing mutant
alleles in animal models of deafness.3,4 Herein, we report
on the use of an artificial microRNA (miRNA)-based
approach to rescuing the progressive hearing-loss pheno-
type in the Beethoven (Bth) mutant mouse, a mouse
model of human autosomal-dominant non-syndromic
hearing loss (DFNA36 [MIM: 606705]). This mouse carries
the semi-dominant Tmc1 c.1235T>A (p.Met412Lys)
allele.5 The encoded protein, TMC1, is a transmembrane
protein with six hydrophobic transmembrane domains
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is assumed to be a component of the mechanoelectrical
transduction complex.8,9 Five mutations have been re-
ported in the human homolog, TMC1 (MIM: 606706],
to cause autosomal-dominant non-syndromic hearing
loss at the DFNA36 locus.10–15 One TMC1 mutation,
c.1253T>A (p.Met418Lys) (GenBank: NM_138691, NCBI
build 36.3), is orthologous to the murine Bth mutation
(Tmc1 c.1235T>A [p.Met412Lys]) and segregates in a large,
222 member Chinese family who suffers from progressive
post-lingual sensorineural hearing loss (Figure 1B). In this
kindred, age of onset varies from 5 to 25 years, potentially
providing a window for therapeutic intervention to pre-
vent the otherwise inevitable deterioration of hearing
thresholds, which by 50 years of age are in the severe-to-
profound range across all frequencies.15 This natural pro-
gression of hearing loss closely mimics the phenotype of
the Bth-heterozygous mouse (Tmc1Bth/þ).
Herein, we report on the use of a single intracochlear in-
jection of an artificial miRNA carried in an adeno-associ-
ated virus (AAV) vector to slow progression of hearing
loss in the Tmc1Bth/þ mutant mouse. In some animals so
treated and otherwise expected to be profoundly deaf by
35 weeks, hearing thresholds were approximately 40 dB
better than those of untreated Tmc1Bth/þ control mice.Material and Methods
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Figure 1. miRNA Design, Screening, and Viral-Vector Selection
(A) Cartoon depiction of a possible configuration of TMC1 highlights the position of the Bth mutation.
(B) Multiple-sequence alignment shows conservation of Met412 in vertebrates and the Met412Lys change in the Tmc1Bth/þ mouse.
(C) siRNA sequence #16 embedded in an artificial miRNA scaffold. Of all miRNAs tested, #16 had the most specific and selective suppres-
sion of themutant Tmc1 c.1235T>A allele. Blue and red arrows depict predicted Drosha and Dicer cleavage sites, respectively; the dashed
box shows the core #16 sequence targeting the mutant Tmc1 variant.
(D) Real-time qPCR analysis of total RNA isolated fromCOS-7 cells cotransfected with constructs expressing bothmiRNA #16 andmiSafe
(a sequence specifically selected for its validated low off-targeting potential6) and either wild-type Tmc1 or mutant Tmc1 c.1235T>A.
Relative mRNA expression levels were calculated with the DDCt algorithm. Error bars represent the SD of three biological and nine
technical replicates.of Iowa Institutional Animal Care and Use Committee (protocol
0608169) approved all relevant procedures.
Mice
All procedures met NIH guidelines for the care and use of labora-
tory animals and were approved by the Institutional Animal
Care and Use Committee at the University of Iowa. Mice were
housed in a temperature-controlled environment on a 12 hr
light-dark cycle. Food and water were provided ad libitum.
Isogenic Bth-heterozygous mice (Tmc1Bth/þ) maintained on a
C3HeB/FeJ (C3H) background were obtained as a gift from Dr.
Karen Steel.5 Inbred wild-type C3H mice were obtained from the
Jackson Laboratory. Crossbred homozygous Tmc1Bth/Bth mice
were caged with wild-type C3H mice for the generation of hetero-
zygous Tmc1Bth/þ animals. Genotyping was done on DNA from
tail-clip biopsies extracted by a phenol-chloroform procedure
and amplified with forward (50-CTAATCATACCAAGGAAACA
TATGGAC-30) and reverse (50-TAGACTCACCTTGTTGTTAATCT
CATC-30) primers in a 25 ml volume containing 150 ng
DNA, 0.2 nM of each primer, and BioLase DNA polymerase
(Bioline) for the generation of a 376 bp amplification product in
Tmc1Bth/þ mice. Amplification conditions included an initial
2 min denaturation at 95C followed by 35 step cycles of 30 s at
95C, 30 s at 57C, and 45 s at 72C and a final elongation of
10 min at 72C. PCR products were purified and sequenced on
an automated sequencer (ABI PRISM model 3730XL, Applied
Biosystems). For mechanotransduction experiments, two geno-
types of Tmc-mutant mice were used (Tmc1þ/;Tmc2/ and
Tmc1Bth/-;Tmc2/) and maintained on a C57BL/6J background
as previously described.161102 The American Journal of Human Genetics 98, 1101–1113, JuneRNAi Oligonucleotide Constructs
The RNAi oligonucleotides and vector plasmids were designed by
the Viral Vector Core at the University of Iowa. Fifteen small inter-
fering RNA (siRNA) sequences, either hand designed or selected
with siSPOTR (siRNA Seed Probability of Off-Target Reduction)
software, were chosen for walking through the target sequence
one base at a time17 (Table S1). Forward and reverse oligonucleo-
tide primers, which included an overlap in the common loop of
the miRNA, were purchased from Integrated DNA Technologies
and used for creating artificial miRNAs. The artificial-miRNA
expression cassette was generated by PCR, purified, and digested
as previously described.17,18 Each artificial-miRNA expression
cassette was cloned into a vector plasmid flanked by inverted ter-
minal repeat sequences and containing the mouse U6 promoter
(mU6) followed by a multiple-cloning site, cytomegalovirus
(CMV)-promoter-driven eGFP, and a Pol II termination signal.
miSafe, a sequence specifically selected for its validated low off-tar-
geting potential, was used as a control.6Virus Production
AAV vectors were prepared by the Viral Vector Core at the Univer-
sity of Iowa by a standard triple-transfection method in 293FT
cells and subsequent purification in a cesium chloride gradient
as previously described.19 For vector selection, single-stranded
recombinant AAV serotypes (rAAV2/1 and rAAV2/9) that carried
CMV-driven eGFP (rAAV2/1eGFP and rAAV2/9eGFP) were
tested. Viral titers used in trans-round-window-membrane
(RWM) injections were rAAV2/1 at 3.09 3 1013 vg/ml and
rAAV2/9 at 1.59 3 1013 vg/ml. The selected therapeutic was2, 2016
single-stranded recombinant AAV serotype 2/9 (rAAV2/9) carrying
a dual transgene cassette of mouse U6-driven miRNA #16, target-
ing the p.Met412Lys-encoding allele and downstream CMV-
driven eGFP (rAAV2/9miTmc1k412.16eGFP [miTmc]). The control
vector wasmU6-drivenmiSafe and downstreamCMV-driven eGFP
(rAAV2/9miSafeGFP [miSafe]).6 Vector titers were determined by
real-time PCR and were miTmc at 1.69 3 1012 and miSafe at
1.39 3 1013 DNase-resistant particles per mililiter. Virus aliquots
were stored at 80C before use.Viral Inoculation
All mice were operated on at postnatal days 0–2 (P0–P2) under
hypothermic anesthesia, for which animals were placed in a
container with crushed ice for 3–5 min. trans-RWM injections
were performed under an operatingmicroscope. First, a post-auric-
ular incision exposed the cochlea bulla, which was opened with
fine forceps. Anatomic landmarks included the RWM and stape-
dial artery, which were identified before injections (Figure S1).
Then, for the trans-RWM injection, either miTmc or miSafe mixed
in a 10:1 ratio with 2.5% fast green dye was loaded into a borosil-
icate glass pipette (1.5 mm outer diameter [OD] 3 0.86 mm inner
diameter [ID], Harvard Apparatus) pulled with a Sutter P-97 micro-
pipette puller to a final OD of ~20 mm and affixed to an automated
injection system pressured by compressed gas (Harvard Appa-
ratus). Pipettes were manually controlled with a micropipette
manipulator. A total volume of 0.5 ml was injected into the left
ear of each mouse. After all procedures, mice were placed on a
heating pad for recovery and rubbed with bedding before being re-
turned to the mother. Recovery was closely monitored daily for at
least 5 days post-operatively.Auditory Testing
The hearing thresholds were recorded in the following groups: (1)
wild-type littermates (C3HeB/FeJ inbred mice: n ¼ 4 from 4 to
13 weeks; n ¼ 5 from 26 to 35 weeks), (2) Tmc1Bth/þ non-injected
mice (n¼ 11), (3) Tmc1Bth/þþmiSafemice (n¼ 13), and (4) rescued
Tmc1Bth/þþmiTmc mice (n ¼ 10).
Auditory testing was conducted in a sound-attenuating room.
Stimulus presentation and recording were controlled with
MATLAB software (MathWorks) running on a PC connected to a
24-bit external sound card (Motu UltraLite mk3) as previously
described.20 Stimuli were delivered via an ER-10Bþ probe micro-
phone (Etymotic Research) connected to two MF1 Multi-Field
Magnetic Speakers (Tucker-Davis Technologies).
Calibration was performed with a 1.125 in microphone placed
in a 0.028 cm3 cavity (length ¼ 0.4 cm; diameter ¼ 0.3 cm), as
shown in Figure S2A. This method of calibration differs from
that of many previous studies that used a standard 2 cm3
coupler (Figure S2B). For a given voltage drive to the loud-
speaker, the sound pressure measured in the smaller cavity will
be much larger than that measured in a 2 cm3 coupler. We based
our calibration on the smaller cavity under the assumption that
the actual pressure experienced at the mouse tympanic mem-
brane is most accurately represented with a cavity that approxi-
mates the size of the mouse ear canal rather than the standard
2 cm3 coupler, which approximates a human ear canal. Measure-
ments in our laboratory showed a 27 dB difference between
pressures measured in the smaller (0.028 cm3) and larger
(2 cm3) couplers. Therefore, when an auditory-brainstem-
response (ABR) threshold is found, the reported sound pressure
delivered by the loudspeaker will depend on the calibration cav-The Americity used. For identical thresholds, the values reported for the
smaller coupler will be 27 dB higher (apparently worse) than
the values reported for the larger coupler. Although the small-
coupler values might reflect sound pressures delivered to the
mouse eardrum more accurately, for ease of direct comparison
to previous studies using C3HeB/FeJ mice, we report ABR thresh-
olds in terms of equivalent 2 cm3 coupler values.21
ABR
Mice were anesthetized with intraperitoneal ketamine and xyla-
zine at 100 and 6 mg per kg of body weight, respectively. ABR
thresholds were obtained for both clicks and tone bursts. Clicks
were square pulses 100 ms in duration. Tone bursts were 3 ms in
length, including 1 ms onset and offset ramps (raised cosine
shape) centered at 8, 16, and 32 kHz. The sweep length for each
stimulus (both click and tone burst) was 29 ms. Between 500
and 1,000 sweeps were averaged at each stimulus level for obtain-
ing the ABR waveforms. All recordings were conducted from both
ears of all animals in a sound-attenuating room.
Distortion-Product Otoacoustic Emissions
Distortion-product otoacoustic emissions (DPOAEs) at 2f1  f2
were measured with f2 frequencies from 4 to 32 kHz in half-octave
steps (f2/f1¼ 1.22). The levels of the primaries were fixed at 65 and
55 dB sound-pressure level (SPL) for f1 and f2, respectively. For
each f2 frequency, ten 1 s stimulus presentations were averaged.
DPOAE amplitudes and associated noise floors were calculated
from fast-Fourier-transform (FFT) analysis of the averaged
waveforms.Immunohistochemistry and Histology
All injected and non-injected cochleae were harvested after ani-
mals were sacrificed by CO2 inhalation. Temporal bones were
removed, perfused with 4% paraformaldehyde, and incubated
for 1 hr. Cochleae were then rinsed in PBS and stored at 4C in
preparation for dissection and immunohistochemistry. Specimens
were visualized with a dissecting microscope and dissected as pre-
viously described.22 Specimens were infiltrated with 0.3% Triton
X-100 and blocked with 5% normal goat serum before tissues
were incubated first in rabbit polyclonal Myosin-VIIA antibody
(Proteus Biosciences) or mouse monoclonal antibody to GFP
(Millipore) diluted at 1:1,000 in PBS for 1 hr and then in a
1:1,000 dilution of the secondary antibody, fluorescence-labeled
anti-rabbit IgG Alexa Fluor 568 or goat anti-mouse IgG Alexa Flour
488 in a 1:2,000 dilution (Invitrogen, Molecular Probes) for
30 min. Filamentous actin was labeled by a 30 min incubation
of phalloidin conjugated to Alexa Fluor 488 (Invitrogen, Molecu-
lar Probes). Specimens were mounted in ProLong Diamond
mounting medium (Life Technologies).
z stack images of whole mounts were collected at 103–403 on a
Leica SP8 confocal microscope (Leica Microsystems). Maximum-
intensity projections of z stacks were generated for each field of
view, and composite images showing the whole cochlea were con-
structed in Adobe Photoshop CS6 in order to meet equal condi-
tions and show the complete turns of the cochlea at high resolu-
tion. Distance from the apex was measured in 0.25 or 0.40 mm
segments with imageJ (NIH Image). For the viral-vector-screening
study, inner hair cells (IHCs) and outer hair cells (OHCs) with
positive eGFP and overlapping MYO7A were counted with ImageJ
Cell Counter. The total number of hair cells and GFP-positive
hair cells were summed and converted to a percentage. For
the miRNA study, IHCs and OHCs with positive MYO7A were
counted with ImageJ Cell Counter; any segments that containedan Journal of Human Genetics 98, 1101–1113, June 2, 2016 1103
dissection-related damage were omitted from the analysis. IHC
and OHC survival was quantified with 203–403 images of
whole-mount cochleae compiled into cochleograms at 35 weeks
as previously described.23Molecular Studies for In Vitro and In Vivo Expression
Analyses
Previously reported cDNAs p.AcGFPmTmc1ex1WT and p.GEMT-
easyTmc1ex1Bth were provided by Dr. Andrew Griffith. p.GEMT-
easyTmc1ex1Bth was PCR amplified with forward (50-GTCGACAG
GATGCCACCCAAAAAAG-30) and reverse (50-ATGGATCCACTG
GCCACCAGCAGC-30) primers containing restriction sites SalI
and BamH1. cDNA inserts were purified by 1% agarose gel electro-
phoresis and QIAquick Gel Extraction (QIAGEN) and subcloned
and ligated into SalI- and BamH-digested p.AcGFP1-N2 vector (cat-
alog no. 632483, Takara Clontech). Successful cloning was verified
with Sanger sequencing (ABI PRISM model 3730XL, Applied
Biosystems).
For in vitro miRNA screening, the aforementioned miRNA
expression plasmids were used. COS-7 cells, which do not contain
native TMC1, were used in this study and grown in DMEM (Invi-
trogen, Thermo Fisher Scientific) with 10% fetal bovine serum at
37C with 5% CO2.
7 Prior to transfection, COS-7 cells were trans-
ferred and grown on a 24-well plate for 1 day. The transfectionmix
was made with Lipofectamine 2000 (Invitrogen, Thermo Fisher
Scientific) according to the manufacturer’s protocol; miRNA
expression plasmids were cotransfected with p.AcGFPmTm-
c1ex1Bth. RNA was extracted from cells with the use of TRIzol
(Invitrogen, Thermo Fisher Scientific). Expression levels were
assessed in triplicate by real-time PCR (StepOnePlus, Applied
Biosystems) with intron-spanning Tmc1 forward (50-GTTC
GCCCAGCAAGATCCTGA-30) and reverse (50-GGATGGTAATCT
TCCAGTTCAGCA-30) primer sets and One Step SYBR PrimeScript
RT-PCR Kit II (Clontech), and results were normalized to b-actin
forward (50-TGAGCGCAAGTACTCTGTGTGGAT-30) and reverse
(50-ACTCATCGTACTCCTGCTTGCTGA-30) primer sets. Controls
included U6 miSafe and empty vector. The miRNA expression
plasmids with greater than 50% suppression were selected and
next cotransfectedwith p.AcGFPmTmc1ex1WT for the assessment
of non-selective suppression of the wild-type allele.
For in vivo expression analysis, the left ear of Tmc1Bth/þ P0–P2
mice was injected with rAAV2/9 carrying miTmc; the right ear
served as a non-injected control. Cochleae were harvested at
P28. eGFP localization in hair cells was confirmed in the apical
turns, which was dissected with a fluorescence dissecting mico-
scope. Cochlear tissue was incubated for 5 min in a collagenase so-
lution at room temperature as previously described.24 To isolate
populations of eGFP-positive hair cells, we isolated hair cells
with a pulled glass micropipette as previously described24 and
added a wash step prior to final collection (Movie S1). We changed
glass pipettes after each isolation to minimize the introduction of
contaminating RNAs into the lysis buffer from either the isolation
buffer or previously isolated cells. GFP-positive hair cells were iso-
lated and placed into tubes containing lysis buffer as previously
described.25 Smart-seq2 protocol steps 1–13 were followed directly
for sample processing from lysis through reverse transcription;
however, the number of cycles in the PCR pre-amplification
(step 14) was reduced to 7 for the purpose of minimizing amplifi-
cation bias. The resulting product was used as the input for SYBR
Green-based qRT-PCR. Allele-specific Bth (50-AAACAGGGTGGGA
CAGAACþT-30) and wild-type Tmc1 (50-AAACAGGGTGGGACAG1104 The American Journal of Human Genetics 98, 1101–1113, JuneAACþA-30) reverse primers were designed with Locked Nucleic
Acid-modified nucleotides on the 30 end, denoted as þT or þA.
These reverse primers were paired with a single forward primer
(50-GCACAGGTGGAGGAGAACAT-30) for the generation of a
219 bp PCR product. Allele specificity was confirmed with plasmid
DNA containing Bth or Tmc1 sequence and optimized at an an-
nealing temperature of 62.5C in Power SYBR Green Master Mix
(Applied Biosystems). qRT-PCRwas carried out with a StepOnePlus
Real-Time PCR System. Each sample was amplified with three
primer sets in triplicate for a total of nine reactions per sample.
Primer sets included primers specific to the wild-type Tmc1 allele,
primers specific to the Bth Tmc1 allele, and b-actin primers. Melt
curves and gel electrophoresis confirmed that PCR products were
primer specific. Results were normalized to b-actin with the
DDCt algorithm.Mechanotransduction
Inner ears of Tmc1Bth/;Tmc2/ mice and littermate control
Tmc1þ/;Tmc2/ mice were injected with 0.5 ml miTmc at
P0–P1 by a trans-RWM approach. Cochleae were harvested at
P8–P10, and the organs of Corti were bathed in standard artificial
perilymph containing 137 mM NaCl, 0.7 mM NaH2PO4, 5.8 mM
KCl, 1.3 mM CaCl2, 0.9 mM MgCl2, 10 mM HEPES, and 5.6 mM
D-glucose. Vitamins (1:50) and amino acids (1:100) were added
to the solution from concentrates (Invitrogen, Thermo Fisher Sci-
entific), and NaOH was used to adjust the final pH to 7.40 (310
mOsm/kg). Recording pipettes (3–5 MU) were pulled from R6
capillary glass (King Precision Glass) and filled with intracellular
solution containing 135 mM CsCl, 5 mM HEPES, 5 mM EGTA,
2.5 mM MgCl2, 2.5 mM Na2-ATP, and 0.1 mM CaCl2; CsOH was
used to adjust the final pH to 7.40 (285 mOsm/kg). Whole-cell,
tight-seal, voltage-clamp recordings were done at 84 mV at
room temperature (22C–24C) with an Axopatch 200B amplifier
(Molecular Devices). Hair bundles were deflected with stiff
glass probes fabricated from capillary glass with a fire polisher
(World Precision Instruments) for creating a rounded probe tip
of ~3–5 mm in diameter. Probes were mounted on a PICMA Chip
piezo actuator (Physik Instrumente) and driven by a 400 mA
ENV400 amplifier (Piezosystem). Sensory-transduction currents
were recorded without knowledge of GFP expression from control
and miTmc-treated hair cells. The data were filtered at 10 kHz
with a low-pass Bessel filter and digitized at R20 kHz with a
16-bit acquisition board (Digidata 1440A, Molecular Devices)
and pClamp 10 software (Molecular Devices). Data were stored
for offline analysis with OriginPro 8 (OriginLab).Statistical Analysis
Statistical analysis of ABR, DPOAE, and cell-counting data was
completed in R with two-sample t tests for samples of equal vari-
ance. Samples with unequal variance were compared with Welch
two-sample t tests. Sample variance was determined with F tests
comparing two variances. All comparisons were made between
the Tmc1Bth/þþmiTmc and Tmc1Bth/þþmiSafe cohorts.Results
RNAi Suppresses the Tmc1 c.1235T>A Allele
We sought to prevent progression of hearing loss in
Tmc1Bth/þ mice by using an artificial miRNA to suppress
the expression of the mutant Tmc1 c.1235T>A allele. Of2, 2016
Figure 2. Evaluation of the Efficiency and Specificity of AAV Transduction
(A) Comparative transduction efficiency and specificity of rAAV2/1 and rAAV2/9 carrying a CMV-eGFP expression construct delivered to
wild-type murine cochlea at P0–P2 via a trans-RWM approach. rAAV2/1 transduces IHCs, OHCs, spiral ganglion cells (arrow), and inner
sulcus cells (arrowhead) in the osseous spiral lamina (OSL). OverlappingMYO7A and eGFP localization represents positive hair cell trans-
duction. Note that compared to rAAV2/1, rAAV2/9 shows specific IHC transduction. Scale bars represent 50 mm.
(B) The efficiency of viral transuction in IHCs was assessed in 400 mmsegments in the apical and basal turns (rAAV2/1 [gray] and rAAV2/9
[black]). Note the high (~74%) rAAV2/9 IHC transduction in the apical turn. Error bars represent the SD (n ¼ 3). *p < 0.05, **p < 0.005.15 miRNA constructs evaluated (Table S1), one miRNA,
#16, was chosen for further study because it robustly and
selectively suppressed the Tmc1 c.1235A allele without
affecting the wild-type allele (Figures 1C and 1D). We
chose to use rAAV2/9 as the delivery vector after we
compared the transduction efficiency of rAAV2/1-eGFP
and rAAV2/9-eGFP injection into the cochleae of wild-
type mice at P0–P2 by a trans-RWM approach. At 2 weeks,
rAAV2/1-eGFP localized to a variety of cell types, including
robust localization in supporting cells; rAAV2/9-eGFP, in
comparison, predominantly localized to IHCs, which
were transduced with 74% efficiency in the apical cochlear
turn (Figures 2A and 2B). The corresponding transduction
of OHCs was 7%. Because IHC dysfunction is primarily
responsible for the deafness phenotype in Tmc1Bth/þ ani-
mals and OHC loss is subtle in the apical cochlear
turns,5,26 we considered the observed levels of hair cell
transduction acceptable for this study.
The miRNA #16 expression cassette was cloned into
rAAV2/9 as a dual transgene cassette of mouse U6-The Americdriven miRNA targeting the p.Met412Lys-encoding tran-
script coupled upstream of CMV-driven eGFP (rAAV2/
9miTmck412.16eGFP, miTmc). A control vector was de-
signed to carry a U6-driven specific sequence selected for
its validated low off-targeting potential and CMV-driven
eGFP (miSafe)6 (Figure 3A). trans-RWM inoculation sur-
gery, whereby 0.5 ml of miTmc or miSafe was injected
into only the left cochlea, was performed on Tmc1Bth/þ
mice at P0–P2 (Figure S1).
We verified robust IHC eGFP localization in cochleae
harvested from Tmc1Bth/þ P0–P2 miTmc-injected mice
2 weeks after surgery, consistent with the transduction
pattern observed in ears injected with rAAV2/9-eGFP
(Figure 3B; Figure S3). To assess in vivo allele-specific sup-
pression in individual hair cells, 4 weeks after surgery we
isolated GFP-positive hair cells from miTmc-injected
cochleae and control hair cells from contralateral non-in-
jected cochleae and completed real-time qPCR by using
primers specific to the wild-type and Bth Tmc1 alleles
(Movie S1). In non-injected ears, the relative expressionan Journal of Human Genetics 98, 1101–1113, June 2, 2016 1105
Figure 3. rAAV2/9-Mediated miTmc Sup-
presses Expression of Tmc1 c.1235T>A
In Vivo
(A) Dual-promoter viral insert in which
the U6 promoter drives miTmc miRNA
expression and the CMV promoter drives
eGFP expression. miSafe was specifically
selected for its validated low off-targeting
potential.24
(B) Two weeks after trans-RWM injection of
miTmc at P0–P2, native eGFP localization
was visible in transduced IHCs and OHCs
in the organ of Corti.
(C) Expression of wild-type Tmc1 and Bth
Tmc1 mRNA was measured by real-time
qPCR using allele-specific primers. Allele-
specific qPCR amplification was carried
out on groups of individually isolated audi-
tory hair cells (Movie S1). All samples were
normalized to b-actin. Expression of wild-
type Tmc1 mRNA measured in the un-
treated contralateral sample was set at a
value of 1. mRNA abundance was calcu-
lated in relation to that of this untreated
contralateral sample with wild-type Tmc1.
Abundance of both wild-type Tmc1 and
Bth Tmc1 were measured in samples con-
taining 12 cells collected from either
miTmc-treated ears or untreated contralat-
eral ears from five 4-week-old Tmc1Bth/þ
mice. Cells collected from untreated
contralateral ears were GFP negative,
whereas cells collected from miTmc-in-
jected ears were GFP positive. mRNA abun-
dance was calculated by the DDCt method.
The range indicated by the error bars repre-
sents the SD of DDCt on the basis of the
fold-difference calculation 2DDCt, where
DDCt þ S and DDCt  S.of the Bth Tmc1 c.1235T>A allele and the wild-type allele
was comparable (Figure 3C). In biological replicates
from miTmc-injected ears, expression of the Bth Tmc1
c.1235T>A allele was suppressed by more than 88% in
comparison to levels of Bth mRNA detected in the sample
from the untreated contralateral ear (Figures 3C).
Mechanotransduction
TMC1 and its closely related ortholog, TMC2, are assumed
to be components of the mechanotransduction channel.
In an earlier report, themutant TMC1 p.Met412Lys variant
was found to reduce calcium permeability and single-chan-
nel currents in IHCs.16 To test the effect of RNAi and allele-1106 The American Journal of Human Genetics 98, 1101–1113, June 2, 2016specific suppression, we therefore
measured transduction currents at
P8–P10 after exposing IHCs to
miTmc. To ensure that observed cur-
rents were only due to expression of
Tmc1, we recorded from mice on a
Tmc2/ background and compared
Tmc1Bth/ mice (carrying only one
mutant Tmc1 allele) to Tmc1þ/ mice
(carrying only one wild-type Tmc1allele) before and after miTmc exposure. Tmc1Bth/ mice
had larger currents than Tmc1þ/ mice, consistent with
data reported by Pan and colleagues.16 miTmc had no ef-
fect on currents observed in Tmc1þ/ mice. In contrast,
exposure to miTmc reduced current amplitudes in
Tmc1Bth/ cells (p < 0.02), consistent with reduced expres-
sion of the mutant allele (Figures 4A and 4B).
miTmc Treatment Prevents Hearing Loss
On the basis of the above results, we completed a longitu-
dinal study to quantitate the effect of miTmc gene therapy
on the hearing-loss phenotype in Tmc1Bth/þ mice
(Figure 5A). To determine how auditory function was
Figure 4. miTmc Lowers Mechanotransduction Currents in Tmc1Bth/ Mice
(A) Families of mechanotransduction currents were recorded from eight different IHCs (P8–P10) under four different conditions. Cur-
rents were evoked by step hair-bundle deflections that ranged in amplitude from 0.2 to 1 mm.
(B) Scatter plot shows maximal mechanotransduction currents recorded from 74 IHCs (open symbols) under four different conditions.
Filled symbols indicate the mean5 SE (box) and SD (bars) for each condition. The number of cells for each condition is indicated at the
bottom.affected, we measured hearing thresholds as ABRs and
DPOAEs in four groups of mice: (1) wild-type littermates,
(2) Tmc1Bth/þ non-injected mice, (3) Tmc1Bth/þþmiSafe
mice, and (4) Tmc1Bth/þþmiTmc mice. ABR thresholds
were assessed as a response to both clicks and tone bursts
at 8–32 kHz, whereas DPOAEs were measured at half-
octave intervals across the same frequency range.
Click ABRs cover a broad frequency and stimulus range
(2–8 kHz and up to 90 dB SPL). We tested animals at
4 week intervals for 35 weeks and documented the ex-
pected deterioration of hearing thresholds in Tmc1Bth/þ
mice, which by 17–21 weeks of age had hearing in the se-
vere-to-profound range (Figure S4). The rate and degree of
hearing loss were consistent with those reported by Nogu-
chi and colleagues and were also seen in the untreated
contralateral right ears of Tmc1Bth/þþmiTmc mice and in
the injected left ears of Tmc1Bth/þþmiSafe mice, demon-
strating that neither the viral inoculation procedure nor
the vector itself added to the decline in auditory func-
tion26 (Figure 5B).
The progression of hearing loss was slower in the
injected left ears of Tmc1Bth/þþmiTmc mice. In all
Tmc1Bth/þþmiTmc mice, preservation of hearing was sig-
nificant in comparison to hearing in controls for up to
21 weeks; however, by 30 weeks ABR thresholds in the
Tmc1Bth/þþmiTmc mice increased (Figure 5B). In the two
best-performing animals, hearing thresholds remained sta-
ble at 15–20 dB above the thresholds of wild-type C3HeB/
FeJ littermate controls for the entire study (Figure 5B). In
these two animals, hearing thresholds remained at least
40 dB better than in untreated Tmc1Bth/þ animals. In the
two worst-performing animals, hearing protection was
lost by 26 weeks.
Frequency-specific effectsweremeasuredwith tone-burst
ABRs (Figures 5Cand5D).Tmc1Bth/þ andTmc1Bth/þþmiSafeThe Americmice both showed abnormal or absent hearing at 16 and
32 kHz by 4 weeks, consistent with earlier reports5,27 (Fig-
ures 5D, 4 weeks). At 8 kHz, ABR responses were >70 dB
by 13 weeks (Figure 5D, 13 weeks). The rate of progression
was not increased in Tmc1Bth/þþmiSafe injected mice, sup-
porting the nontraumatic nature of the trans-RWM injec-
tion at P0–P2.
In the left ears of Tmc1Bth/þþmiTmc mice, there was
significant preservation of hearing at 8 and 16 kHz 4 weeks
after treatment, although there was no protective effect at
32 kHz (Figures 5D, 4 weeks). By 13 weeks after injection,
the protective effect at 16 kHz was lost; however, at 8 kHz a
significant protective effect still remained (Figures 5C and
5D, 13 weeks). In the two best-performing animals, hearing
thresholds at 8 kHz were preserved throughout the entire
study period (dashed blue line); thresholds were stable and
only mildly higher than those of wild-type littermate con-
trols (solid black line) (Figure 5D, 4–35 weeks; Figure S5).
We also measured 8 kHz wave I amplitudes at 4 weeks as
a measure of synaptic integrity. The treated left ears in
Tmc1Bth/þþmiTmc mice had smaller amplitudes overall
than did those of wild-type littermate controls. Wave I am-
plitudes were even smaller in Tmc1Bth/þþmiSafe mice and
continued to dampen at 8 weeks. In the Tmc1Bth/þþmiTmc
mice, the wave I amplitudes remained stable (Figures S6A
and S6B).
DPOAEs are an objective measure of OHC function and
were recorded at the same time points as the ABRs. Con-
sistent with prior reports, we found DPOAE recordings
to be comparable between Tmc1Bth/þ mice and wild-type
controls, reflecting a high degree of OHC preservation in
the cochlear apex26 (Figure 5E, 4–35 weeks). At ultra-
high frequencies (22–32 kHz), we did identify a DPOAE
decline in Tmc1Bth/þ mice (Figure 5E, 4–35 weeks). miTmc
treatment did not affect DPOAEs in the first few weeksan Journal of Human Genetics 98, 1101–1113, June 2, 2016 1107
Figure 5. miTmc Gene Therapy Slows Progression of Hearing Loss in Tmc1Bth/þ Mice
(A) Experimental timeline catalogs the experimental procedures in Tmc1Bth/þmice and controls from the time of artificial miRNA injec-
tion to the time of tissue collection.
(B) Click ABR thresholds in wild-type,Tmc1Bth/þþmiTmc contralateral, Tmc1Bth/þþmiSafe, and Tmc1Bth/þþmiTmc animals. The two best-
performing and two worst-performing Tmc1Bth/þþmiTmc-treated animals are shown as dashed and dotted blue lines, respectively, to
illustrate variability in performance within the treated cohort.
(C) Representative 8 kHz ABR traces recorded from the wild-type, non-injected Tmc1Bth/þþmiTmc contralateral, and Tmc1Bth/þþmiTmc
13-week-old mice.
(D and E) Tone-burst ABR thresholds (D) and DPOAE amplitudes and noise floors (E) in wild-type, Tmc1Bth/þ, Tmc1Bth/þþmiSafe, and
Tmc1Bth/þþmiTmc animals at 4, 8, 13, 26, and 35 weeks. The dotted black line indicates the average noise floor for each group of
DPOAEs. Black arrows indicate no response at equipment limits. *p < 0.05, **p < 0.005. See also Figures S4 and S5.
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of the study, and at 4 weeks, we observed no differences
between Tmc1Bth/þþmiTmc and Tmc1Bth/þþmiSafe mice.
By 8 weeks, however, whereas Tmc1Bth/þþmiSafe mice
showed a sharp decline in DPOAEs in the ultra-high-fre-
quency range, DPOAEs in Tmc1Bth/þþmiTmc mice were
maintained (Figures 5E, 8 weeks). This difference persisted,
consistent with some preservation of OHCs in the basal
turn of the cochlea in Tmc1Bth/þþmiTmc mice (Figure 5E,
4–35 weeks).
In summary, a single injection of miTmc significantly
slowed progression of hearing loss in Tmc1Bth/þ mice for
approximately 21 weeks. At the end of the 35-week study
period, the two best-performing Tmc1Bth/þþmiTmc mice
had hearing thresholds that were only 15–20 dB above
thresholds for wild-type C3HeB/FeJ littermate controls.
These thresholds were approximately 40 dB better than ex-
pected in the absence of treatment.
miTmc Improves Hair Cell Survival
The histological correlate of auditory function in Tmc1Bth/þ
mice is hair cell survival. To quantitate the effect of miTmc
on hair cell survival, we counted hair cells in 0.25 mm
segments from cochlear whole mounts in four groups: (1)
wild-type littermates, (2) Tmc1Bth/þþmiTmc mice, (3)
Tmc1Bth/þþmiSafe mice, and (4) Tmc1Bth/þ non-injected
mice.
Consistent with reported data, in Tmc1Bth/þ mice IHC
loss was more pronounced than OHC loss and occurred
in a base-to-apex gradient.26 By 35 weeks, we found com-
plete IHC loss in the basal turn and 40%–50% IHC loss
in the apical turn (Figures 6A and 6B, Tmc1Bth/þ). As ex-
pected, there was no IHC or OHC loss in 35-week-old
wild-type control animals (Figures 6A and 6B, wild-type).
Hair cell survival in all Tmc1Bth/þþmiSafe-treated
left ears was indistinguishable from hair survival in
Tmc1Bth/þ mice (Figures 6A and 6B, Tmc1Bth/þþmiSafe
and Tmc1Bth/þ). In contrast, Tmc1Bth/þþmiTmc mice
showed markedly improved hair cell survival (Figures 6A
and 6B, Tmc1Bth/þþmiTmc). IHC counts in Tmc1Bth/þ
þmiTmc mice were greatest in the apical region of the
cochleae (10%–20%), and visible gaps occurring in the
mid-modiolar region (40%–50%) showed inter-animal
variability. In the lower mid-modiolar to basal regions of
the cochleae (60%–70%), the pattern of IHC loss was
indistinguishable between Tmc1Bth/þþmiTmc mice and
Tmc1Bth/þ and Tmc1Bth/þþmiSafe mice. When we
compared the entire Tmc1Bth/þþmiTmc cohort to the two
best performers, we observed only a slight difference in
mean IHC survival in the apical to mid-modiolar regions
of the cochleae (10%–50%; Figure 6C). Compared to
Tmc1Bth/þþmiSafe animals, Tmc1Bth/þþmiTmc mice
showed minimal improvement in OHC survival in the api-
cal 10% of the cochleae and in the lower mid-modiolar to
basal regions of the cochlea, although these differences
were not significant. OHC survival was otherwise compara-
ble between Tmc1Bth/þþmiTmc and Tmc1Bth/þ animals
(Figure 6D).The AmericWe also examined stereocilia-bundle morphology in sur-
viving hair cells in both the best-performing and worst-
performing Tmc1Bth/þþmiTmc mice alongside Tmc1Bth/þ
and wild-type controls at 35 weeks (Figure S7). In the
Tmc1Bth/þþmiTmc mice, stereocilia bundles appeared to
be thinner but nevertheless well organized and compara-
ble to those of wild-type controls in the apical regions; in
the basal region, any remaining stereocilia bundles were
sparse and distorted. This apex-to-base gradient of stereoci-
lia-bundle degeneration is consistent with earlier observa-
tions in Tmc1Bth/þ mice.5,27 In Tmc1Bth/þ mice, fewer sur-
viving hair cells remained, and in those cells, the
stereocilia bundles were distorted or absent (Figure S7,
Tmc1Bth/þ). We observed no difference between the two
best performers and the entire cohort treated with
Tmc1Bth/þþmiTmc (Figure S7).Discussion
This report demonstrates that using RNAi to suppress
expression of an endogenous deafness-causing allele can
slow progression of hearing loss. We selectively suppressed
the Tmc1 c.1235T>A (p.Met412Lys) dominant gain-of-
function allele in Tmc1Bth/þmice at an early developmental
stage. We were able to prevent profound hearing loss from
developing for over 35 weeks (the duration of the study) in
someanimals otherwisedestined tohave severe toprofound
levels of deafness across all frequencies by 17–21 weeks.
Treatment with miTmc also appeared to have a particularly
striking protective effect on hair cell survival. Compared
to Tmc1Bth/þþmiSafe and Tmc1Bth/þ non-injected mice,
Tmc1Bth/þþmiTmc mice showed significantly enhanced
IHC survival in the apical turn of the cochlea. Although
the reasons for enhanced IHC survival remain to be deter-
mined, these observations are consistent with both the
pattern of rAAV2/9 transduction and audiometric data.
In the majority of Tmc1Bth/þþmiTmc mice, a single in-
jection of miTmcmaintained hearing acuity for ~26 weeks.
Thereafter, the protective effect of miTmc on hearing
was variable, a result consistent with well-documented
differences in the efficiency and longevity of viral trans-
duction.22,28,29 For example, Akil et al. used trans-RWM in-
jection of AAV1-Vglut3 to restore hearing in neonatal
Vglut3/ mice and observed variable degrees of hearing
loss 7 weeks after treatment.28 Kim et al. used in utero
rAAV2/1-MsrB3 (methionine sulfoxide reductase B3) to
rescueMsrB3/mice and showed hearing deterioration af-
ter 4 weeks.30
There are also reports of successful restoration of normal
inner-ear morphology but failed restoration of auditory
function after inner-ear gene therapy employing AAV vec-
tors. Chien et al. attempted to restore hearing in deaf
whirler (whirlin/) mice with trans-RWM injections of
AAV8-Whirlin, and although they demonstrated restored
morphology of the stereocilia, hearing sensitivity was not
rescued.31 Similarly, attempts using AAV1-Gjb2 to restorean Journal of Human Genetics 98, 1101–1113, June 2, 2016 1109
Figure 6. miTmc Gene Therapy Improves Hair Cell Survival
Wild-type, Tmc1Bth/þ, Tmc1Bth/þþmiSafe, and Tmc1Bth/þþmiTmc animals sacrificed 35 weeks after treatment. Ears were fixed, dissected,
and stained as cochlear whole mounts.
(A) 103 images of representative whole-mount apical turns from wild-type, Tmc1Bth/þþmiTmc, Tmc1Bth/þþmiSafe, and Tmc1Bth/þ ani-
mals. Samples were stained with MYO7A (red) and phalloidin (green) for labeling hair cells and filamentous actin, respectively. Arrow-
heads show the apical tip and 8 and 16 kHz regions along the apical turn of the cochlea. Note IHC preservation in the Tmc1Bth/þþmiTmc
animals. The white cross shows the area devoid of IHCs. Scale bars represent 150 mm.
(B) 403magnification at the indicated position in relation to the cochlear apex. The three rows of OHCs (1–3), pillar cells (P), and IHCs
are shown. Areas with dark hallows illustrate OHC or IHC loss. The white cross shows the area devoid of IHCs. Scale bars represent 50 mm.
(C and D) IHC (C) and OHC (D) survival was quantified with 203–403 images of whole-mount cochlea compiled into cochleograms
at 35 weeks. Hair cells were counted in 0.25 mm segments and plotted against the distance (%) from the apex. Tmc1Bth/þþmiSafe,
Tmc1Bth/þþmiTmc, and Tmc1Bth/þþmiTmc best performers (n ¼ 2) are shown. *p < 0.05, **p < 0.005.
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hearing in cCX26 knockout mice by Yu et al. demonstrated
restoration of gap-junction function in supporting cells
without successful hearing restoration.32 Explanations for
this dichotomy have included (1) injection methods, (2)
injection timing, (3) promoter types, (4) vector serotypes,
and (5) transduction efficiency.
The low rate of viral transduction appears to be the most
common conclusion for unsuccessful restoration of hear-
ing sensitivity and could be the reason for the variability
observed in our study as well. Indeed, although we
achieved high viral transduction in the apical turn and
observed hearing preservation at 8 kHz, transduction in
the lower turns was very low, and at 32 kHz, the progres-
sion of hearing loss was not affected. These observations,
however, do not explain the hearing deterioration we
documented in themajority of treatedmice after 26 weeks.
The longevity of rAAV therapeutics is believed to main-
tain stable transgene expression for a year or longer, as
noted in studies of human gene therapy with AAV2-
hRPE65v2 in Leber’s congenital amaurosis.33 One explana-
tion for the time-limited hearing preservation we observed
could be the natural progression of OHC loss that occurs in
Tmc1Bth/þ mice in a base-to-apex gradient overtime,
although this loss is minimal in the apical region at
20 weeks.26 An alternate explanation could be the vari-
ability of RNAi in Tmc1Bth/þþmiTmcmice at the molecular
level, which leads to early loss of the RNAi-mediated effect.
Side effects of RNAi include miRNA off-target effects, satu-
ration of miRNA endogenous machinery, and immune
stimulation via siRNA.34 A combination of these side ef-
fects could possibly lead to molecular changes at the hair
cell level, although we did not observe structural damage,
significant IHC loss, or signs of inflammation even in
treated animals that were profoundly deaf at the end of
the study, suggesting that miTmc gene therapy did not
cause oto-toxicity at the cellular level. Further studies will
be needed to improve OHC transduction and to investigate
any long-term consequences of RNAi-mediated gene ther-
apy at the molecular level.
Missense mutations underlie 85% of all human auto-
somal-dominant non-syndromic hearing loss, raising the
possibility that an RNAi-based therapeutic strategy could
be broadly applicable to this type of hearing loss.35 Target-
ing autosomal-dominant non-syndromic hearing loss
would be attractive because this type of loss is postlingual
and progressive, thus providing a large window of opportu-
nity for surgical intervention with a miRNA-based gene-
silencing strategy. Prior to any clinical trial, however,
several challenges must be addressed. First, although this
and other studies attest to the value of mouse models for
testing different forms of gene therapy directed at hearing
preservation or restoration,28,36 because functional matu-
ration of the cochlea occurs during the second postnatal
week in mice and during the third trimester in humans,
direct translation of these studies across species is not
possible. Additional studies in rodents must focus on the
age at injection, which remains a potential challenge givenThe Americthat transduction efficiency of inner-ear structures appears
to be inversely related to the postnatal time of exposure.
Target tissue must also be addressed because although
HCs express one-third of all genes known to be associated
with deafness37—which makes them excellent transduc-
tion candidates—efforts to effectively and selectively target
other cells must be established.
Route of injection and vector choice must be optimized.
Because of the small volume of the inner ear, direct-injec-
tion techniques will limit the total number of viral-
genome-containing particles per mililiter that can be deliv-
ered, suggesting that alternative approaches should be
explored to permit higher total injection loads. These ex-
periments will require testing a variety of vectors to define
the injection route, injection time, and inner-ear cell spec-
ificity for each. Finally, the possibility that therapeutic
intervention after hearing loss begins could improve
some genetic types of deafness if irreversible damage has
not occurred should be explored.
Many of these questions will be addressed with murine
models of hearing loss, but ultimately proof-of-concept
studies in non-human primates will be needed to confirm
vector trophism for specific types of inner-ear cells in the
absence of off-target effects. Clinical trials will then be
possible. Their designmight require the recruitment of per-
sons with gene-specific or even mutation-specific types of
hearing loss, a selection process that will be facilitated
through genetic databases that many laboratories are
maintaining on persons who receive comprehensive ge-
netic testing as part of their clinical diagnostic evaluation
for hearing impairment.
We believe that preventing hearing loss in an organ
destined to fail presents fewer challenges than restoring
function in a cochlea that has already undergone substan-
tial degenerative changes. Thus, although using gene ther-
apy to replace lost hair cells or regrow inner-ear architecture
is likely to be exceedingly difficult, its use for replacing
defective genes, suppressing a deafness-causing allele, or
correcting abnormal splicing before cochlear damage is
rampant might be more feasible. Because substantial chal-
lenges remain in using gene therapy to restore the func-
tional integrity of this unique and complex organ, we
believe that efforts to prevent autosomal-dominant non-
syndromic hearing loss warrant a concerted effort by the
research community as an example of ‘‘low-hanging fruit.’’Supplemental Data
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